GlassScriptPhysician profile
Steve I Chang
NPI 1295897569
$21,146.16
in general payments reported to CMS, 2019-2025
58 companies · $2,641 in 2025
The $2,641 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,082 · 2020: $2,317 · 2021: $3,460 · 2022: $3,299 · 2023: $3,332 · 2024: $3,015 · 2025: $2,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,968 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,967.80 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,572.48 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,773.93 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Astrazeneca Pharmaceuticals LP | $1,404.37 | 2019-2025 | Lokelma, Airsupra, Breztri |
| Pfizer INC. | $1,349.45 | 2019-2025 | |
| Abbvie INC. | $1,318.69 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,231.50 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $946.85 | 2019-2024 | Myrbetriq, Veozah |
| Amneal Pharmaceuticals LLC | $905.57 | 2019-2024 | Rytary, Unithroid, Ongentys |
| Janssen Pharmaceuticals, INC | $804.58 | 2019-2023 | Xarelto |
| Ucb, INC. | $725.37 | 2021-2025 | Briviact, Nayzilam |
| Novartis Pharmaceuticals Corporation | $724.50 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $685.54 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $573.61 | 2021-2025 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $546.87 | 2020-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $502.79 | 2021-2025 |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.